These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 15039807)

  • 1. [Severe sepsis treated with activated protein C].
    Frøyshov S; Jacobsen D; Bjertnaes L; Flaatten H
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):779-81. PubMed ID: 15039807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel treatment for severe sepsis: recombinant human protein C (RHAPC)].
    Uszyiński W; Uszyński M; Lisiecki A
    Ginekol Pol; 2005 Nov; 76(11):913-20. PubMed ID: 16566369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.
    Dahabreh Z; Dimitriou R; Chalidis B; Giannoudis PV
    Expert Opin Drug Saf; 2006 Jan; 5(1):67-82. PubMed ID: 16370957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
    De Backer D
    Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].
    Heslet L; Nielsen JD; Schierbeck J; Andersen JS
    Ugeskr Laeger; 2004 Mar; 166(11):997-1002. PubMed ID: 15049234
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
    Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL
    Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
    Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
    Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
    Vincent JL; Bernard GR; Beale R; Doig C; Putensen C; Dhainaut JF; Artigas A; Fumagalli R; Macias W; Wright T; Wong K; Sundin DP; Turlo MA; Janes J
    Crit Care Med; 2005 Oct; 33(10):2266-77. PubMed ID: 16215381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Bartelink AK
    Ned Tijdschr Geneeskd; 2006 Feb; 150(7):352-4. PubMed ID: 16523795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated protein C (Xigris) treatment in sepsis: a drug in trouble.
    Gårdlund B
    Acta Anaesthesiol Scand; 2006 Sep; 50(8):907-10. PubMed ID: 16923083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management challenge with drotrecogin alfa (activated).
    Vanscoy GJ
    Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S23-9. PubMed ID: 11885411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study.
    de Pont AC; Bakhtiari K; Hutten BA; de Jonge E; Vroom MB; Meijers JC; Büller HR; Levi M
    Crit Care; 2005 Oct; 9(5):R490-7. PubMed ID: 16277710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis.
    Goldstein B; Nadel S; Peters M; Barton R; Machado F; Levy H; Haney DJ; Utterback B; Williams MD; Giroir BP
    Pediatr Crit Care Med; 2006 May; 7(3):200-11. PubMed ID: 16575354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human-activated protein C (rhAPC) in childhood sepsis.
    Frassica JJ; Vinagre YM; Maas B
    J Intensive Care Med; 2004; 19(1):56-7. PubMed ID: 15035756
    [No Abstract]   [Full Text] [Related]  

  • 17. Drotrecogin alfa (activated) approved for treatment of severe sepsis.
    Poe K
    J Am Pharm Assoc (Wash); 2002; 42(3):520-2. PubMed ID: 12030642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated protein C for severe sepsis.
    Garces K
    Issues Emerg Health Technol; 2002 Mar; (30):1-4. PubMed ID: 11985365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard GR; Vincent JL; Laterre PF; LaRosa SP; Dhainaut JF; Lopez-Rodriguez A; Steingrub JS; Garber GE; Helterbrand JD; Ely EW; Fisher CJ;
    N Engl J Med; 2001 Mar; 344(10):699-709. PubMed ID: 11236773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.